Sigilon Therapeutics Stock News

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -19.57% and 47.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference. The presentation will take place on Tuesday, March 15, 2022 at 10:45 a.m. EDT and will be followed by a 25-minute Q&A break out session.

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Sigilon Therapeutics, Inc. (SGTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio

BMEZ: Buy Low, Hold For The Distribution And Rebound

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded

Sigilon Therapeutics Inc (SGTX) shares closed 4.4% lower than its previous 52 week low, giving the company a market cap of $73M. The stock is currently down 17.0% year-to-date, down 93.4% over the past 12 months, and down 93.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 41.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 463.2% The company's stock price performance over the past 12 months lags the peer average by 206.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sigilon Therapeutics Inc (SGTX) shares closed today at 0.9% above its 52 week low of $2.27, giving the company a market cap of $77M. The stock is currently down 13.0% year-to-date, down 93.1% over the past 12 months, and down 93.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 61.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -2258.1% The company's stock price performance over the past 12 months lags the peer average by 224.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) have been given a consensus rating of Buy by the six brokerages that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers []

- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization

Goldman Sachs Group Inc. lifted its holdings in Sigilon Therapeutics, Inc. (NASDAQ:SGTX) by 70.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,552 shares of the companys stock after buying an additional 13,903 shares during the period. Goldman Sachs Group []

Sigilon Therapeutics (NASDAQ:SGTX) had its price objective lowered by Morgan Stanley from $9.00 to $4.50 in a research report released on Tuesday morning, Analyst Ratings Network reports. Morgan Stanley currently has an equal weight rating on the stock. Several other research firms have also weighed in on SGTX. Zacks Investment Research lowered shares of Sigilon []

BTIG Research reaffirmed their buy rating on shares of Sigilon Therapeutics (NASDAQ:SGTX) in a report released on Tuesday morning, AnalystRatings.com reports. BTIG Research currently has a $14.00 target price on the stock. Several other research firms have also recently weighed in on SGTX. Canaccord Genuity increased their price objective on Sigilon Therapeutics from $23.00 to []

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 419,900 shares, a decrease of 37.0% from the October 31st total of 666,000 shares. Currently, 3.0% of the companys stock are sold short. Based on an average trading volume of []